Over 200 years of experience
in the pharmaceutical industry
FDF, API, CMO, CDMOPharmaceutical development and manufacturing
-
Contract manufacturing
Learn moreWe specialise in the production of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). Our production lines for highly potent medicines (OEB 5) are among the most advanced in Central and Eastern Europe. We operate in full compliance with EU cGMP, FDA and EAEU standards.
-
Laboratory services
Learn moreWe offer comprehensive preformulation and analytical support. In 2025, we launched a state-of-the-art laboratory for highly potent parenteral products (OEB 5). Our team performs over 4,000 tests annually.
Over 50 products in 130 forms and doses
We manufacture prescription (Rx) medicines – antibiotics, human insulins, CNS and dermatological products – as well as over-the-counter (OTC) medicines, dietary supplements and dermocosmetics. Every year, we deliver over 25 million packages to hospitals, pharmacies and healthcare institutions, supporting the health and well-being of patients worldwide.
View portfolioWe manufacture in Poland
– for a safer tomorrow
We are the oldest pharmaceutical company in Poland and one of the oldest in Europe. Since 1823, we have been building the foundations of Polish pharmacy by introducing groundbreaking solutions. We were the first in the country to start producing penicillin, insulin and antibiotics, setting new standards in treatment. Today, we produce 10% of the medicines classified as critical by the European Union, helping to secure treatment access for millions of patients.
News
-
23.10.2025AnnouncementsCenter for Development and Production of Highly Potent Drugs
TZF Polfa, a Polish pharmaceutical manufacturer, proudly presents its latest venture in Warsaw – the Center for Development and Production of Highly Potent Drugs, one of the most advanced injectable drug manufacturing facilities in Europe. This technologically advanced plant fully meets the growing global demand for injectable medicines in various pharmaceutical forms. The facility covers […]Read more -
06.03.2026TendersRequest fot quotatnion – RFQ Z2/5438/1 – Study monitoring – Empagliflozin
In connection with the implementation of the project 2022/ABM/04/00014-00 – „Opracowanie i rozwój produktu leczniczego z substancją czynną EMPAGLIFLOZYNĄ – leku generycznego na cukrzycę typu 2” (”Design and development of a medicinal product with the active substance EMPAGLIFLOZIN – a generic drug for type 2 diabetes”), Tarchominskie Zakłady Farmaceutyczne POLFA S.A. invites you to submit […]Read more -
05.03.2026Announcements
Selection procedure for the position of President of the Management Board
The Supervisory Board of Tarchomińskie Zakłady Farmaceutyczne “Polfa” S.A., with its registered office in Warsaw, hereby announces a selection procedure for the position of President of the Management Board. Written applications should be sent by post to the Company’s address (Tarchomińskie Zakłady Farmaceutyczne “Polfa” S.A., ul. A. Fleminga 2, 03-176 Warsaw) or delivered in person […]Read more -
05.03.2026Announcements
Selection procedure for the position of First Member of the Management Board
The Supervisory Board of Tarchomińskie Zakłady Farmaceutyczne “Polfa” S.A., with its registered office in Warsaw, hereby announces a selection procedure for the position of First Member of the Management Board. Written applications should be sent by post or delivered in person to the Company Authorities Support Department (ul. A. Fleminga 2, 03-176 Warsaw) by March […]Read more -
05.03.2026Announcements
Selection procedure for the position of Second Member of the Management Board
The Supervisory Board of Tarchomińskie Zakłady Farmaceutyczne “Polfa” S.A., with its registered office in Warsaw, hereby announces a selection procedure for the position of Second Member of the Management Board. Written applications should be sent by post to the Company’s address (Tarchomińskie Zakłady Farmaceutyczne “Polfa” S.A., ul. A. Fleminga 2, 03-176 Warsaw) or delivered in […]Read more -
20.01.2026For patients
Availability of Elenium
Warsaw, January 20, 2026 Elenium Availability Dear Sir or Madam, Following the administrative decision of the Chief Pharmaceutical Inspectorate to withdraw from the market certain batches of the medicinal product: Elenium 5 mg, coated tablets Elenium 10 mg, coated tablets Elenium 25 mg, coated tablets we would like to provide […]Read more -
01.12.2025For patients
Distribution of PolhuminPen injectors
Dear Patients and Doctors, Please be advised that PolhuminPen® injectors are distributed free of charge exclusively as part of a patient program for individuals requiring insulin therapy. To facilitate access to injectors, doctors can order them online at: 👉 https://tzfpolfapromed.pl/ Thank you for working with us to ensure the comfort and safety of patients!Read more -
23.10.2025Announcements
Success in the development of the medicinal product Dapagliflozinum 10 mg
We are pleased to announce that the newly developed medicinal product Dapagliflozinum, 10 mg, coated tablets, has successfully passed bioequivalence testing. The project is co-financed from the state budget by the Medical Research Agency as part of project No. 2022/ABM/04/00021 – “Development and advancement of a medicinal product with the active substance dapagliflozin – a […]Read more
